stoxline Quote Chart Rank Option Currency Glossary
Jaguar Health, Inc. (JAGX)
4.03  -0.6 (-12.96%)    05-28 16:00
Open: 4.76
High: 4.7999
Volume: 1,324,823
Pre. Close: 4.63
Low: 4.02
Market Cap: 20(M)
Technical analysis
2024-05-28 4:53:50 PM
Short term     
Mid term     
Targets 6-month :  8.46 1-year :  9.88
Resists First :  7.24 Second :  8.46
Pivot price 1.11
Supports First :  2.84 Second :  0.12
MAs MA(5) :  2.81 MA(20) :  0.9
MA(100) :  0.26 MA(250) :  0.34
MACD MACD :  0.8 Signal :  0.3
%K %D K(14,3) :  62.7 D(3) :  44.5
RSI RSI(14): 78.1
52-week High :  7.24 Low :  0.05
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ JAGX ] has closed below upper band by 8.4%. Bollinger Bands are 2507.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 27 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.81 - 4.84 4.84 - 4.87
Low: 3.95 - 3.98 3.98 - 4.01
Close: 3.98 - 4.03 4.03 - 4.08
Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Headline News

Tue, 28 May 2024
Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea - WSIL TV

Sun, 26 May 2024
Jaguar Health (NASDAQ:JAGX) Sees Strong Trading Volume - Defense World

Fri, 24 May 2024
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49% - Simply Wall St

Fri, 24 May 2024
Jaguar Health (NASDAQ:JAGX) Now Covered by - Defense World

Thu, 23 May 2024
What's Going On With Jaguar Health Stock? - Jaguar Health (NASDAQ:JAGX) - Benzinga

Thu, 23 May 2024
Jaguar Health stock down on reverse stock split (NASDAQ:JAGX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 287 (M)
Held by Insiders 2.743e+008 (%)
Held by Institutions 7.8 (%)
Shares Short 19,710 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.191e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -312.5 %
Return on Assets (ttm) -43.2 %
Return on Equity (ttm) -2 %
Qtrly Rev. Growth 9.76e+006 %
Gross Profit (p.s.) -32.67
Sales Per Share 407.35
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -33 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 51.81
Stock Dividends
Dividend 0
Forward Dividend 1.433e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android